These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 14668034)

  • 1. Lamivudine therapy in acute leukemia patients who are hepatitis B surface antigen carriers.
    Yilmaz M; Dagdas S; Güler N; Aki SZ; Aköz AG; Özet G; Ayli M; Saritas U
    Hematology; 2003 Dec; 8(6):393-6. PubMed ID: 14668034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lamivudine prophylaxis for hepatitis B virus carrier patients with breast cancer during adjuvant chemotherapy.
    Lee HJ; Kim DY; Keam B; Lee JH; Han SW; Oh DY; Yoon JH; Kim TY; Kim YJ; Lee KW; Kim JW; Jeong SH; Lee JS; Kim JH; Im SA
    Breast Cancer; 2014 Jul; 21(4):387-93. PubMed ID: 23073741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lamivudine therapy for a hepatitis B surface antigen (HBsAg)-positive leukemia patient receiving myeloablative chemotherapy and autologous stem cell transplantation.
    Uchida N; Gondo H; Himeji D; Kaji Y; Sata M; Niho Y
    Bone Marrow Transplant; 2000 Dec; 26(11):1243-5. PubMed ID: 11149741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation.
    Giaccone L; Festuccia M; Marengo A; Resta I; Sorasio R; Pittaluga F; Fiore F; Boccadoro M; Rizzetto M; Bruno B; Marzano A
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):809-17. PubMed ID: 20060484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy.
    Leaw SJ; Yen CJ; Huang WT; Chen TY; Su WC; Tsao CJ
    Ann Hematol; 2004 May; 83(5):270-5. PubMed ID: 15060745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy.
    Rossi G; Pelizzari A; Motta M; Puoti M
    Br J Haematol; 2001 Oct; 115(1):58-62. PubMed ID: 11722410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fatal reactivation of hepatitis B virus in a patient who was hepatitis B surface antigen negative and core antibody positive before receiving chemotherapy for non-Hodgkin lymphoma.
    Wu JM; Huang YH; Lee PC; Lin HC; Lee SD
    J Clin Gastroenterol; 2009; 43(5):496-8. PubMed ID: 19247200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylaxis against chemotherapy-induced reactivation of hepatitis B virus infection with Lamivudine.
    Simpson ND; Simpson PW; Ahmed AM; Nguyen MH; Garcia G; Keeffe EB; Ahmed A
    J Clin Gastroenterol; 2003 Jul; 37(1):68-71. PubMed ID: 12811213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors.
    Prakoso E; Strasser SI; Koorey DJ; Verran D; McCaughan GW
    Clin Transplant; 2006; 20(3):369-73. PubMed ID: 16824156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation.
    Castells L; Vargas V; Rodríguez F; Allende H; Buti M; Sánchez-Avila JF; Jardí R; Margarit C; Pumarola T; Esteban R; Guardia J
    Liver Transpl; 2002 Oct; 8(10):892-900. PubMed ID: 12360430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lamivudine for the prevention of hepatitis B virus reactivation after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with advanced or relapsed non-Hodgkin's lymphoma single institution experience.
    Huang H; Cai Q; Lin T; Lin X; Liu Y; Gao Y; Peng R
    Expert Opin Pharmacother; 2009 Oct; 10(15):2399-406. PubMed ID: 19761353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lamivudine prophylaxis and treatment of hepatitis B Virus-exposed recipients receiving reduced intensity conditioning hematopoietic stem cell transplants with alemtuzumab.
    Moses SE; Lim ZY; Sudhanva M; Devereux S; Ho AY; Pagliuca A; Zuckerman M; Mufti GJ
    J Med Virol; 2006 Dec; 78(12):1560-3. PubMed ID: 17063522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B virus infection.
    Ahmed A; Keeffe EB
    Am J Gastroenterol; 1999 Jan; 94(1):249-51. PubMed ID: 9934765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease.
    Chen FW; Coyle L; Jones BE; Pattullo V
    Liver Int; 2013 Sep; 33(8):1203-10. PubMed ID: 23522150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcome after prophylactic lamivudine treatment on hepatitis B virus reactivation in non-Hodgkin's lymphoma.
    Kim JS; Hahn JS; Park SY; Kim Y; Park IH; Lee CK; Cheong JW; Lee ST; Min YH
    Yonsei Med J; 2007 Feb; 48(1):78-89. PubMed ID: 17326249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lamivudine monoprophylaxis for de novo HBV infection in HBsAg-negative recipients with HBcAb-positive liver grafts.
    Vizzini G; Gruttadauria S; Volpes R; D'Antoni A; Pietrosi G; Filì D; Petridis I; Pagano D; Tuzzolino F; Santonocito MM; Gridelli B
    Clin Transplant; 2011; 25(1):E77-81. PubMed ID: 21039887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study.
    Seto WK; Chan TS; Hwang YY; Wong DK; Fung J; Liu KS; Gill H; Lam YF; Lie AK; Lai CL; Kwong YL; Yuen MF
    J Clin Oncol; 2014 Nov; 32(33):3736-43. PubMed ID: 25287829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers.
    Shibolet O; Ilan Y; Gillis S; Hubert A; Shouval D; Safadi R
    Blood; 2002 Jul; 100(2):391-6. PubMed ID: 12091327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prophylactic use of lamivudine can maintain dose-intensity of adriamycin in hepatitis-B surface antigen (HBs Ag)-positive patients with Non-Hodgkin's lymphoma who receive cytotoxic chemotherapy.
    Lee GW; Ryu MH; Lee JL; Oh S; Kim E; Lee JH; Kim SB; Kim SW; Suh C; Lee KH; Kim WK; Lee JS; Kang YK
    J Korean Med Sci; 2003 Dec; 18(6):849-54. PubMed ID: 14676442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum hepatitis B surface antigen kinetics in severe reactivation of hepatitis B e antigen negative chronic hepatitis B patients receiving nucleoside/nucleotide analogues.
    Wong GL; Chan HL; Lo AO; Chan HY; Tse CH; Chim AM; Wong VW
    Antivir Ther; 2013; 18(8):979-86. PubMed ID: 23744529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.